Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

3953 - Use of lipegfilgrastim for the prophylaxis of chemotherapy-induced neutropenia: pan-European non-interventional study

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Supportive Care and Symptom Management

Tumour Site

Presenters

Guenther Steger

Citation

Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300

Authors

G. Steger1, P. Pichler2, M. Airoldi3, P. Mazza4, C. Fontaine5, J. Timmer Bonte6, J.A. Walewski7, J. Katolicka8, M. Mikulova9, M. Gasparic10

Author affiliations

  • 1 Department Of Medicine I, Oncology Division, Medical University Vienna; Gaston H. Glock Research Center, 1090 - Vienna/AT
  • 2 Innere Medizin 1, Landesklinikum St. Poelten, 3100 - St. Poelten/AT
  • 3 Oncologia Medica, AOU S. Giovanni Battista - Molinette, 10126 - Torino/IT
  • 4 Hematology, SS Annunziata Hospital, 74100 - Taranto/IT
  • 5 Medical Oncology, Vrije Universiteit Brussel-Campus Jette, 1090 - Brussels/BE
  • 6 Medical Oncology, Alexander Monro Breast Cancer Clinic, 3720 AD - Bilthoven/NL
  • 7 Lymphoid Malignancies, The Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), 02-781 - Warsaw/PL
  • 8 Medical Oncology, St. Anne's University Hospital Brno, 62100 - Brno/CZ
  • 9 Medical Oncology, St. Elisabeth Cancer Institute, 81250 - Bratislava/SK
  • 10 Medical Affairs Europe, Teva Pharmaceuticals Europe B.V., 1019 GM - Amsterdam/NL
More

Resources

Abstract 3953

Background

Lipegfilgrastim (Lonquex®) is a long-acting glycopegylated G-CSF, which was proven to be non-inferior to pegfilgrastim in breast cancer patients. The objectives of this study were to evaluate effectiveness and safety of lipegfilgrastim in everyday clinical practice in adult patients with different tumor types, who are treated with cytotoxic chemotherapy.

Methods

Patients with different tumor types treated with cytotoxic chemotherapy, who received lipegfilgrastim in primary (PP) or secondary prophylaxis (SP) were included in this prospective non-interventional study. Evaluation of chemotherapy (CT) and biological therapy (BT) dose modifications as well as neutropenic events following the first lipegfilgrastim supported treatment cycle is presented here.

Results

A total of 1,313 patients were included in the safety set. Mean age of included patients was 58.4±13.3 and 70.2% were female. The majority of patients had breast cancer (46.7%) and lymphoma (26.4%). A total of 895 (68.2%) patients received lipegfilgrastim in PP starting from CT cycle 1 and 192 (14.6%) patients received it in SP for the first time. They were included in the effectiveness analysis. In the first cycle febrile neutropenia (FN) was reported in 1.8% of patients receiving lipegfilgrastim in PP and in 1.0% of patients receiving lipegfilgrastim in SP. Grade 3/4 neutropenia was reported in 7.5% (PP) and 6.7% (SP) of patients. CT and/or BT was delayed, reduced or omitted in 20.1% of patients receiving lipegfilgrastim in PP and in 28.1% of patients receiving it in SP. This was associated with FN and grade 3/4 neutropenia in only 1.0% and 2.2% of these patients in case of PP and 2.1% and 5.5% in case of SP. A total of 284 (21.6%) patients reported at least one adverse drug reaction (ADR) throughout the study. The most common ADRs were bone pain (5.86%), myalgia (3.43%) and back pain (1.83%). Serious ADRs were reported by 42 (3.2 %) of patients.

Conclusions

Lipegfilgrastim is effective and well tolerated in the real world setting administered either in PP or SP. Both effectiveness and safety data obtained in this study are in line with published data for lipegfilgrastim.

Clinical trial identification

Legal entity responsible for the study

Teva.

Funding

Teva.

Editorial Acknowledgement

Disclosure

G. Steger, P. Pichler, M. Airoldi, P. Mazza, C. Fontaine, J. Timmer Bonte, J.A. Walewski, J. Katolicka, M. Mikulova: Investigator in Teva sponsored study. M. Gasparic: Employee: Teva Pharmaceuticals Europe B.V.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.